Astrazeneca (AZN) Tumbles 2.82% Amid Broader Market Decline: Q1 Earnings Preview

Astrazeneca (AZN) stock dipped by 2.82% to close at $183.60, trailing the S&P 500's 1.51% loss. The pharmaceutical company's earnings per share are projected to be $2.5, with revenue expected to rise 9.02% YoY. AZN's full-year Zacks Consensus Estimates predict earnings of $10.31 per share and revenue of $62.86 billion, representing year-over-year changes of +12.55% and +7.01%, respectively. The Zacks Rank system, which takes estimate changes into account, currently ranks AZN as a #3 (Hold).